Cure Alzheimer's Fund Cure Alzheimer's Fund

Understanding the Role of Natural Amyloid Beta-Specific B Cell Responses in Alzheimer’s Disease Progression

2021, 2023

The U.S. Food and Drug Administration recently approved aducanumab, an antibody that promotes clearance of amyloid beta plaques in patients with Alzheimer’s disease. Here we propose to study whether Alzheimer’s disease is associated with the development of natural antibodies against amyloid beta plaques, whether these antibodies attenuate disease progression and whether their presence can help identify patients who will benefit from antibody therapy.

Marco Colonna Studies of Innate Immune Pathology Translational

Funding to Date

$345,000

Focus

Studies of Innate Immune Pathology, Translational

Researchers

Marco Colonna, M.D.

Related Content:


Probing the Molecular Underpinnings of G Protein-Coupled Receptor ADGRG1 Mediated Protective Microglial Responses to Alzheimer’s disease Xianhua Piao 2024-10-31 Multidimensional Profiling of TREM2-Mutated or APOE4-mutated Microglia in Human Brain Organoids to Understand Dysregulated Microglia Neuronal Crosstalk in Alzheimer’s Disease Florent Ginhoux 2024-10-31 Impact of DNA Damage-Mediated Stimulator of Interferon Genes (STING) Activation on Myelin Function in an Alzheimer’s Disease Animal Model Alban Gaultier 2024-09-24 Targeting Reactive Astrocytes AMPK Signaling to Suppress Inflammation in Alzheimer’s Disease Gilbert Gallardo 2024-09-16 Contributions of IL34 Signaling to Microglial Function and Alzheimer’s Pathology in Mice Staci Bilbo 2024-09-16 Meningeal Regulatory T-Cells (Tregs) in Individuals with Versus without Alzheimer’s Disease Diane Mathis 2024-09-16 Elucidating Mechanisms Driving the Compromised Balance Between Mitophagy and cGAS-STING-Initiated Inflammation Towards a Treatment for Alzheimer’s Disease Per Nilsson Evandro F. Fang 2024-08-22 Investigating Alzheimer’s Disease-Associated Membrane Biology in Microglia and Neurons Anna Greka Beth Stevens 2024-05-31